Figure 2
Figure 2. Overall and relapse-free survival according to FLT3-ITD allelic ratio and type of postremission therapy. Simon Makuch plots illustrating the influence of postremission treatment modality on OS in (A-B) first CR and (C-D) RFS according to FLT3-ITD AR in FLT3-ITD–positive AMLs with (A,C) high (≥0.51) or (B,D) low (<0.51) AR.

Overall and relapse-free survival according to FLT3-ITD allelic ratio and type of postremission therapy. Simon Makuch plots illustrating the influence of postremission treatment modality on OS in (A-B) first CR and (C-D) RFS according to FLT3-ITD AR in FLT3-ITD–positive AMLs with (A,C) high (≥0.51) or (B,D) low (<0.51) AR.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal